A Study of IBR854 Combined With Pazopanib Versus Pazopanib in Advanced Renal Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 10, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Renal Cell Carcinoma (RCC)
Interventions
DRUG

IBR854

Every 21 days is one cycle, and IBR854 will be dosed in a route of intravenous infusion on day 1 and day 8 of each cycle with a fixed dose of 9.0×10\^9 cells.

DRUG

Pazopanib

Pazopanib will be dosed orally once daily without food (at least 1 hour before or 2 hours after a meal) with a fixed dose of 800mg.

Trial Locations (1)

Unknown

The Cancer Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Imbioray (Hangzhou) Biomedicine Co., Ltd.

INDUSTRY